In this materials perspective, the promise of water based layer-by-layer (LbL) assembly as a means of generating drug-releasing surfaces for biomedical applications, from small molecule therapeutics to biologic drugs and nucleic acids, is examined. Specific advantages of the use of LbL assembly versus traditional polymeric blend encapsulation are discussed. Examples are provided to present potential new directions. Translational opportunities are discussed to examine the impact and potential for true biomedical translation using rapid assembly methods, and applications are discussed with high need and medical return.
technique through various means of passive and active film disassembly, destabilization, or degradation. In the next decade, it will be important to move LbL approaches beyond laboratory successes and toward clinical translation. Such translation relies on the ability to show the power of multilayer systems in meaningful biomedical applications, as well as the potential for commercial manufacturability of the LbL process. The field has been growing rapidly, and many researchers have contributed to the development of new LbL drug delivery systems 7, 9, 22 ; in this review perspective, a few selected examples from our research team will be provided in three general areas. Among the systems discussed, emphasis is placed on those that have been demonstrated with in vitro and in vivo studies, and on demonstrations of the use of rapid assembly and versatile LbL application methods that can help to move LbL biomaterials systems from lab to clinic with true translation to pharmaceutical and biomedical applications.
Controlling release of therapeutics from surfaces
A unique advantage to the use of LbL assembly is its ability to incorporate drugs in high concentrations within a multilayer thin film. Traditional polymers used in blends with small molecules for release matrices can generally only incorporate 2 to 5 wt% drugs while maintaining reasonable stability; larger quantities tend to lead to phase separation, destabilization of the blend, and bolus release behavior. In an alternating LbL assembly that consists of two to four components, for example, the direct adsorption of a pharmaceutical actually utilizes the drug as one of the layers within the film, stabilized by electrostatic, hydrogen bonding, or a combination of these interactions. The loading of drugs at high densities -often ranging from 10 to 40 wt% -with nanofilms that can conformally coat a broad range of surfaces creates new opportunities for the release of therapeutic molecules from surfaces for localized drug release.
Gentamicin is a simple, water soluble aminoglycoside that kills bacterial cells by inhibiting their protein synthesis; it is commonly used in hospital settings to address Pseudomonas aeruginosa, Escherichia coli, Staphylococcus (Staph) and other common bacterial species for skin, bone, and soft tissue infections 23 . When introduced orally, gentamicin only resides in the body for a few hours before being eliminated, thus significantly lowering the impact of the antibiotic on a local infected region. On the other hand, gentamicin has been introduced into polymer composites such as methyl methacrylate based bone cement used for securing whole joint orthopedic implants to prevent infections 24 . The limitation of such systems is that gentamicin can only be incorporated into the cement at low concentrations without sacrificing the integrity of the polymer cement -thus it cannot be used to eliminate an existing infection 25 . By directly layering the positively charged gentamicin sulfate (GS) drug molecule with negatively charged polyelectrolytes in an alternating LbL tetralayer with a degradable polycation and a biologically derived polyanion, it is possible to generate gentamicin release thin films that are on the micron to submicron scale in terms of thickness, and provide uniform coatings on biomedical implants such as orthopedic implants, sutures, cardiovascular, and opthalmalogical implants 26, 27 . The degradable component utilized in this example was a poly(β-aminoester) (PBAE), shown as Poly1 in Fig. 2a , which is layered with GS and polyacrylic acid (PAA) 27 . When LbL multilayers are built from the repeat {Poly1/PAA/ GS/PAA}, the final thin film exhibits a large rapid release of gentamicin from the surface, followed by sustained release over multiple weeks; this release behavior is due to freely absorbed GS molecules incorporated into the film in the final step GS absorption step, yielding a combination release mechanism of rapid drug out-diffusion plus slow hydrolytic degradation of GS containing layers. In the example shown in Fig. 2b , 200 tetralayer films release a total of 550 μg/cm 2 of gentamicin sulfate from a titanium implant surface, with an initial rate over the first few days of 11 μg/cm 2 /day, followed by a constant linear release over the following four week period of 4 μg/cm 2 /day. The gentamicin released from the films retains all of its activity, maintaining the same potency as the free drug (Fig. 2c ). More important with regard to the translation of this kind of approach for biomedical implants is the demonstration that the released antibiotic can lower infection in vivo. Using a rabbit bone infection model, titanium inserts coated with the LbL gentamicin film were shown to alleviate even very severe established bone infection in animals 27 (Fig. 2d, e) . There are numerous important therapeutics that are not charged, and do not necessarily have good water solubility. In these cases, it is possible to adapt LbL to a range of different carrier species that can readily be introduced into multilayer systems. For example, polycyclodextrins (PolyCDs) with charged groups can be used to sequester hydrophobic drugs such as anti-inflammatory agents, and subsequently can be layered into multilayer thin films to create stable thin films 28 . A series of non-steroidal anti-inflammatory drugs (NSAIDs) 29 were examined for the assembly of a negatively charged PolyCD-NSAID complex with PBAE's that exhibit different rates of hydrolytic degradation 28 . By varying the composition of degradable polycation chosen, the rate of degradation could be modulated in these systems. On the other hand, for any given degradable polyion, the normalized rates of drug release were statistically identical regardless of which NSAID was incorporated, yielding a controlled and constant release over multiple days and demonstrating a platform technology that enables the incorporation of many different molecules while achieving predictable release characteristics. The NSAIDS examined, including commonly used diclofenac and flurbiprofen, exhibited cyclooxygenase (Cox-2) inhibition when released in vitro to cells stimulated to yield an inflammatory response. Release in these films is linear with no initial bolus. Therapeutic levels of drug are eluted from film coatings just a few hundred nanometers in thickness, with release over several days to over four weeks. Hydrophobic antibiotics, including Ciproflaxin, which is a broad spectrum antibiotic known for its high efficacy, can also be delivered in its active form using PolyCD complexes 28 . The films themselves are clear, thin, highly conformal, and exhibit excellent optical properties; ongoing work is now targeted toward development of these films for opthalmological applications such as intraocular lenses.
It is also possible to combine the technique of direct drug incorporation with the use of a carrier such as a PolyCD; this kind of approach has been successfully demonstrated with the generation of LbL delivery thin 35 by permission of The Royal Society of Chemistry.
Fig. 3 (a) Photograph image and (b) TEM micrograph of a cross-section of free-standing (PEO-b-PCL/PAA)60 film. (c) Once films are constructed, thermal cross-linking significantly enhances the stability of the film and slows the drug release profile. (d) Change of film thickness as measured by profilometry. The thickness of the as-prepared film rapidly decreases upon introduction to PBS buffer, whereas the cross-linked films undergo much slower film deconstruction. (e) cross-linked film releases drugs over an extended period of time, (six days for two ourh cross-link, thirteen days for 39 hour cross-linked film). Reproduced from
films that simultaneously release the broad spectrum charged antibiotic vancomycin and an anti-inflammatory drug 30 .
Micelles, liposomes or other colloidal carriers and nanomaterials such as nanoparticles may also be used as drug carriers that can be directly introduced into multilayer thin films [31] [32] [33] [34] . Of particular interest is the use of simple FDA approved components to generate thin films with a broad range of release behaviors. It is possible to generate alternating multilayers of the water soluble and biologically safe poly(ethylene oxide) (PEO) with poly(acrylic acid) (PAA) at low pH through hydrogen bonding between the PEO ether oxygens and the PAA acid groups. We have used this knowledge as the basis for the design of LbL thin films consisting of alternating drug loaded micelles from block copolymers of polycaprolactone (PCL)-PEO with moderate to high molecular weight PAA 35 . The films that are formed at low pH are micron-scale in thickness, and generate coatings or cohesive free-standing films, as shown in Fig. 3 35 . When these thin films are exposed to a plasma pH of 7.4, the acid groups become highly charged, the hydrogen bonds are disrupted, and electrostatic repulsion causes the film to rapidly disassemble, releasing its contents and dissolving entirely in a matter of seconds. Such a rapid release approach may be of interest for the rapid delivery of agents to a wound site or the release of oral therapeutics on the tongue or cheek, for example. On the other hand, this same LbL assembly can be treated using heat, or other methods to dehydrate the film and generate anhydride bonds between carboxylic acid groups in 42 with permission from Wiley.
Fig. 4 Hemostat sponge created for battlefield medicine applications contain LbL films with blood clotting protein, thrombin (shown in a). (b) Spray-LbL enables the uniform coating of hydrogen bonded LbL thin films on a highly porous absorbent sponge. (c) In vitro hemostatic activity of film coated gelatin sponge. (d) Time to hemostasis following sample applicaon (controls were sponges with a monolayer coating of BPEI). Reproduced from
the film. Such films erode away at a much slower rate, dependent on the degree of anhydride crosslinking, leading to a near-linear release of the same cargo over two weeks. The micellar nanocarriers, when released, can penetrate the surrounding tissue of an implant, wound bed, or surgical incision and deliver cargo to these localized regions following the hydrolytic breakdown of the PCL core, which is prone to take place over longer time periods than the anhydride. Use of a different hydrogen bonding component, such as a polyphenol like tannic acid 36 , yields a different set of release conditions and systems that can be incorporated into the film. The hydrogen bonding of PEO based micelles with tannic acid, for example, generates films that are stable above pH 7.4, thus allowing the integration of a broad range of components at biologic pH or lower 35 .
For direct translation of these systems toward realistic applications, we can introduce a means of rapidly assembling LbL coatings on a variety of surfaces. One approach that has proven to be particularly versatile is the use of Spray-LbL 37-41 , in which each alternating component is introduced via a short spray exposure of aqueous polyelectrolyte or drug solution, followed by a spray rinse. Because each cycle for adsorption is reduced to a few seconds, this approach is orders of magnitude faster than traditional dip-LbL methods; however, another important advantage in the biomedical arena is that it allows us to coat a wider variety of surfaces. Flat and uniform, dimensionally complex, and highly porous substrates all become available for LbL application using this approach. Particularly challenging surfaces include those that are both porous and water absorbent, such as gelatin sponges that were designed to absorb many times their weight in blood plasma to address bleeding and help induce hemostasis. Thrombin (Fig. 4a) , a native protein that induces rapid hemostasis in a wound by triggering a part of the blood clotting cascade, was introduced in a layer-by-layer thin film through the simple alternation of thrombin with tannic acid 42 based on hydrogen bonding interactions between the protein and the small molecule, which is a key component found in teas and wine tannins, and a natural anti-oxidant 43 . As shown in Fig. 4b and c, the original porous morphology of the sponge is preserved using vacuumassisted Spray-LbL; the film conformally coats the surfaces of the pores without significantly filling the pores, leaving them free and accessible for water uptake. The thrombin contained within the films was found to be fully active when compared to the free protein, and large therapeutic amounts of active thrombin can be incorporated into the sponge due to its large surface area. When tested in vivo with a pig spleen bleeding model, it was found that upon compression on a heavily bleeding wound, even a 10-bilayer treated LbL thrombin gelatin sponge can stop bleeding at least three times faster, than the uncoated gelatin sponge.
Broad spectrum antibiotics, such as vancomycin, can also be coated on these sponges to yield systems that remain functional, and can even improve the sponge absorbency 44 . The ability to coat micro and even nanoporous materials leads to numerous possibilities in the areas of wound care, control of adhesions for surgical implants, and ready storage of localized medical treatments in general for emergency care.
New LbL routes to tissue regeneration
An exciting area in which multilayer assembly presents true potential is regenerative medicine and tissue engineering 4, 7, 45, 46 . A number of highly sensitive growth factors regulate the differentiation, proliferation, and signaling of stem cells that determine the formation of new tissues and key processes such as wound healing. These growth factors are typically administered directly to tissues of interest with bolus injections, or encapsulated in depots that lead to bolus release in the body; such mass release of growth factor proteins generally leads to a large amount of clearance of the active protein, with only a small amount of the expensive biologic therapeutic remaining to exact 60 with permission from Elsevier.
Fig. 6 Combination BMP-2/VEGF growth factors yield higher bone density within implants. Growth factor loading was controlled by varying the number of layers dipped on the scaffold. rhBMP-2 released over a period of about one to two weeks, whereas rhVEGF eluted completely within a shorter time period of four to six days depending on number of layers used. (a) Release profiles for BMP containing films. (b) Release profiles of VEGF containing films. (c) (Top row) Micro CT results of bone tissue formation. Control scaffolds without growth factors produce no detectable bone over the duration of the study (Middle row) In single growth factor rhBMP-2 films lacking rhVEGF165, bone formation is restricted to the periphery of the scaffold at four weeks and nine weeks. (Bottom row) As a result of increased vascularity, scaffolds releasing rhVEGF165 demonstrate a smooth, continuous profile in the ectopically formed bone which matures from four weeks to nine weeks to fill the entire scaffold. Reproduced from
its influence on tissue development [47] [48] [49] . A more extended release of smaller, controlled quantities of growth factor would generally replicate the natural process of tissue generation, while yielding a controlled and localized process with high pharmacological yield;
however, most polymeric carriers can only contain limited amounts of protein in a stable blend formulation due to thermodynamic and other practical constraints. Furthermore, key to the maintenance of protein activity is the avoidance of solvent, higher temperatures, or pH conditions sufficient to denature proteins, conditions that are commonly needed to achieve solubilization in traditional materials systems. A unique aspect of LbL assembly is the fact that it is an all-aqueous, room temperature process that can be readily adapted to the incorporation of a broad range of proteins at high loadings 50 .
When incorporated from aqueous solutions at appropriate pH and ionic strength, it has been shown that proteins in LbL films retain their higher order structure and activity [51] [52] [53] For tissues to integrate effectively into a scaffold or around an implant, typically a vascular system that is well-developed is needed to provide blood, oxygen and nutrients via blood flow, and a pathway for cell precursors to populate the developing tissue 56, 59 . We investigated the construction of separate sets of LbL films containing the vascular endothelial growth factor (VEGF), which recruits endothelial precursors and enables angiogenesis, and BMP2 60 . By generating a series of LbL nanolayers that release VEGF, atop a series containing BMP2, it is possible to observe the simultaneous but independent release of the two factors, with VEGF releasing over a period of two to three days and BMP2 releasing over a more extended time period of five to seven days (Fig. 6a) . The amount of protein released in each case at different rates from a number of surfaces, and lift-off methods can be used to generate free-standing micron-scale elements, which may be of interest for microparticle delivery systems. An earlier approach to electrochemically stimulated release was first observed when redox-active Prussian Blue (iron hexacyanoferrate) nanoparticles, capable of undergoing changes in charge from −2 to neutral, were introduced into films in the charged state; when small potentials were switched on in the film, the negative charge was reversibly removed, causing the film to destabilize due to charge imbalance 67 .
In more systematic studies, it was possible to show the release of large macromolecules 68 , and finally of a small molecule drug such as gentamicin with films of Prussian Blue 69 , which is a safe, FDA approved compound often used for the treatment of heavy metals, as shown in Fig. 8 ; the films can be systematically pulsed multiple times to release controlled nano-to microgram quantities of drugs. More recently, it has also been possible to generate electrically controlled release systems based on the localized disruption of hydrogen bonding in LbL thin films composed of biocompatible components 70 .
In general, numerous approaches to microfabrication and LbL thin film manipulation can lead to unique micro-delivery methods that can be accessed using a broad range of triggers -from temperature to remote control field-assisted release.
Conclusions
In 
